Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Taylor D. Coe"'
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-8 (2018)
Abstract Background Drug-drug interactions (DDIs) in subjects enrolling in clinical trials can impact not only safety of the patient but also study drug outcomes and data validity. This makes it critical to adequately screen and manage DDIs. The stud
Externí odkaz:
https://doaj.org/article/11b006ae8c3343bd8f828972bbeba9cb
Autor:
Taylor D. Coe, Siu-Fun Wong, Bruce G. Redman, Lauren A Marcath, Edward Reynolds, Mike Bayuk, Steven Haas, Daniel L. Hertz, Faisal Shakeel
Publikováno v:
J Patient Saf
OBJECTIVES: Screening subjects for drug-drug interactions (DDI) prior to enrollment in oncology clinical trials is integral to ensuring safety, but standard procedures or tools are not readily available to screen DDI in this setting. Our objective wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82d99768f1866c15a3df22c27846aea6
https://doi.org/10.1097/pts.0000000000000772
https://doi.org/10.1097/pts.0000000000000772
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-8 (2018)
BMC Cancer
BMC Cancer
Background Drug-drug interactions (DDIs) in subjects enrolling in clinical trials can impact not only safety of the patient but also study drug outcomes and data validity. This makes it critical to adequately screen and manage DDIs. The study objecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14aeaad23cfcba14dbb64a7dd589c50e
http://link.springer.com/article/10.1186/s12885-018-5076-0
http://link.springer.com/article/10.1186/s12885-018-5076-0
Publikováno v:
Journal of Clinical Oncology. 36:315-315
315 Background: Screening drug-drug interactions (DDI) for subjects enrolling in oncology clinical trials is critical to ensuring patient safety and the validity of clinical trial data. We previously reported that DDI screening is not uniformly condu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::66aa4577fbf498b43fcf3ced117557b9
https://doi.org/10.1200/jco.2018.36.30_suppl.315
https://doi.org/10.1200/jco.2018.36.30_suppl.315
Publikováno v:
Journal of Clinical Oncology. 36:e18819-e18819
e18819Background: Oncology patients are at high risk of clinically relevant drug-drug interactions (DDIs) due to high rates of polypharmacy. DDIs in patients enrolled in clinical trials can adverse...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45cf72e62cbed2d07eb5cfd0663ea738
https://doi.org/10.1200/jco.2018.36.15_suppl.e18819
https://doi.org/10.1200/jco.2018.36.15_suppl.e18819